US2004259227A1PendingUtilityA1

Strains of bacteria and pharmaceutical composition containing one or more of such strains and use of same for preventing and treating diseases asociated with or caused by altered metabolism of bile acids

53
Priority: Mar 11, 1996Filed: Aug 21, 2003Published: Dec 23, 2004
Est. expiryMar 11, 2016(expired)· nominal 20-yr term from priority
Inventors:Renata Maria Anna Cavaliere VeselyClaudio De SimoneMarco Vesely
A61P 1/00A61K 31/575A61K 35/747A61K 31/7016A61P 1/16C12N 1/20A61K 35/74C12R 2001/46C12R 2001/225A61K 35/744C12N 1/205
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Strains of bacteria characterized by exhibiting: (a) a 7α-dehydroxylase activity of less than 50%, and (b) a bile acid deconjugation activity of less than 50%, and descendants, mutants and derivatives thereof preserving activities (a) and (b); and a pharmaceutical composition using one or more of such strains and use of same for preventing and treating diseases associated with or caused by an altered metabolism of bile acids.

Claims

exact text as granted — not AI-modified
1 - 11 . cancel  
     
     
         12 . A pharmaceutical composition for preventing and/or treating diseases associated with or caused by an altered metabolism of bile acids, comprising an effective amount capable of producing a normalizing effect on such an altered metabolism in a patient suffering therefrom, of (1) at least one bacteria strain provided with: (a) a 7 α-dehydroxylase activity of less than 50%, and (b) a bile acid deconjugation activity of less than 50%, and descendants, mutants and derivatives thereof preserving activities (a) and (b), and (2) a pharmaceutically acceptable carrier.  
     
     
         13 . The pharmaceutical composition of  claim 12 , wherein said at least one bacteria strain is a gram-positive bacteria strain.  
     
     
         14 . The composition of  claim 12 , wherein said at least one bacteria strain belongs to a species selected from the group consisting of  Streptococcus thermophilus, Streptococcus faecium , and  Lactobacillus bulgaricus.    
     
     
         15 . The composition of  claim 14 , wherein the bacteria strain is  Streptococcus thermophilus  YS 52 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1670.  
     
     
         16 . The composition of  claim 14 , wherein the bacteria strain is  Streptococcus thermophilus  YS 46 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1668.  
     
     
         17 . The composition of  claim 14 , wherein the bacteria strain is  Streptococcus thermophilus  YS 48 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1669.  
     
     
         18 . The composition of  claim 14 , wherein the bacteria strain is  Streptococcus faecium  SF 3 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1671.  
     
     
         19 . The composition of  claim 14 , wherein the bacteria strain is  Lactobacillus bulgaricus  LB 1 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1664.  
     
     
         20 . The composition of  claim 14 , wherein the bacteria strain is  Lactobacillus bulgaricus  LB 3 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1665.  
     
     
         21 . The composition of  claim 14 , wherein the bacteria strain is  Lactobacillus bulgaricus  LB 7 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1666.  
     
     
         22 . The composition of  claim 14 , wherein the bacteria strain is  Lactobacillus bulgaricus  LB 77 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1667.  
     
     
         23 . The composition of  claim 12 , comprising 10 3  to 10 13  cells of the bacteria strain per gram of composition.  
     
     
         24 . The composition of  claim 12 , further comprising lactulose.  
     
     
         25 . The composition of  claim 12 , further comprising bile acid-based preparations, such as ursodeoxycholic acid and tauroursodeoxycholic acid.  
     
     
         26 . A method for preventing and treating diseases caused by or associated with an altered metabolism of bile acids, said method comprising administering at least one bacteria strain characterized by exhibiting: 
 (a) a 7 α-dehydroxylase activity of less than 50%, and    (b) a bile acid deconjugation activity of less than 50%, and descendants, or a mutant or derivative thereof preserving activities (a) and (b).    
     
     
         27 . method of  claim 26 , wherein the at least one bacteria strain is a gram-positive bacteria strain.  
     
     
         28 . The method of  claim 26 , wherein the bacteria strain belongs to a species selected from the group consisting of  Streptococus thermophilus, Streptococcus faecium , and  Lactobacillus bulgaricus.    
     
     
         29 . The method of  claim 28 , wherein the bacteria strain is  Streptococcus thermophilus  YS 52 deposited with the CNCM, Collection Nationale de Culturess de Microorganismes, Institut Pateur, under the accession number I-1670.  
     
     
         30 . The method of  claim 28 , wherein the bacteria strain is  Streptococus thermophilus  YS 46 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1668.  
     
     
         31 . The method of  claim 28 , wherein the bacteria strain is  Streptococcus thermophilus  YS 48 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1669.  
     
     
         32 . The method of  claim 28 , wherein the bacteria strain is  Streptococcus faecium  SF 3 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes,Institut Pasteur, under the accession number I-1671.  
     
     
         33 . The method of  claim 28 , wherein the bacteria strain is  Lactobacillus bulgaricus  LB 1 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1664.  
     
     
         34 . The method of  claim 28 , wherein the bacteria strain is  Lactobacillus bulgaricus  LB 3 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1665.  
     
     
         35 . The method of  claim 28 , wherein the bacteria strain is  Lactobacillus bulgaricus  LB 7 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1666.  
     
     
         36 . The method of  claim 28 , wherein the bacteria strain is  Lactobacillus bulgaricus  LB 77 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1667.

Join the waitlist — get patent alerts

Track US2004259227A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.